157 related articles for article (PubMed ID: 32257944)
1. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Park R; Lopes L; Cristancho CR; Riano IM; Saeed A
Front Oncol; 2020; 10():258. PubMed ID: 32257944
[No Abstract] [Full Text] [Related]
2. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor.
Sawada T; Narukawa M
Cancer Control; 2024; 31():10732748241244586. PubMed ID: 38581169
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis.
Shen X; Yang J; Qian G; Sheng M; Wang Y; Li G; Yan J
Front Oncol; 2024; 14():1391724. PubMed ID: 38826783
[TBL] [Abstract][Full Text] [Related]
5. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
[TBL] [Abstract][Full Text] [Related]
6. The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review.
Machado AP; Ratliff H; Abdelwahab A; Vohra MH; Kuang A; Shatila M; Khan MA; Shafi MA; Thomas AS; Philpott J; Alhalabi O; Wang Y
J Cancer; 2023; 14(16):2956-2963. PubMed ID: 37859810
[No Abstract] [Full Text] [Related]
7. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.
Kovalenko I; Lynn Ng W; Geng Y; Wang Y; Msaouel P; Bhatia S; Grivas P; Benkhadra R; Alhalabi O
Front Oncol; 2023; 13():1238517. PubMed ID: 38239644
[TBL] [Abstract][Full Text] [Related]
8. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Liu T; Jin B; Chen J; Wang H; Lin S; Dang J; Li G
Ther Adv Med Oncol; 2020; 12():1758835920940927. PubMed ID: 32774474
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis.
Curkovic NB; Bai K; Ye F; Johnson DB
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254829
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis.
Li J; Zhu JX; Zhang YX; Li SQ
Oncol Lett; 2024 Apr; 27(4):153. PubMed ID: 38406596
[TBL] [Abstract][Full Text] [Related]
11. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database.
Kuo HT; Chen CY; Hsu AY; Wang YH; Lin CJ; Hsia NY; Tsai YY; Wei JC
Front Immunol; 2023; 14():1302293. PubMed ID: 38264654
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Li P; Hu M; Liu M; Ren X; Liu D; Liu J; Yin J; Tan X; Cao G
Front Oncol; 2023; 13():1197782. PubMed ID: 37817769
[TBL] [Abstract][Full Text] [Related]
13. Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Vardarli I; Tan S; Brandenburg T; Weidemann F; Görges R; Herrmann K; Führer D
J Clin Endocrinol Metab; 2024 Mar; 109(4):1132-1144. PubMed ID: 37967245
[TBL] [Abstract][Full Text] [Related]
14. Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.
Lima IG; Silva IBUCD; Pípolo VC; Delfino VDA; Bignardi PR
Immunopharmacol Immunotoxicol; 2024 Jun; ():1-12. PubMed ID: 38825890
[TBL] [Abstract][Full Text] [Related]
15. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L; Sakka M; Retbi A; Bouam S; Hassani L; Meritet JF; Rufat P; Bonnefont-Rousselot D; Batista R; Terris B; Bellanger A; Thabut D; Vozy A; Spano JP; Coriat R; Goldwasser F; Aractingi S; Sogni P; Pol S; Mallet V; ;
JHEP Rep; 2023 Dec; 5(12):100880. PubMed ID: 38074948
[TBL] [Abstract][Full Text] [Related]
16. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis.
Tang Q; Wu D; Huang H; Fang H; Wu Y; Liu F; Li N
Front Pharmacol; 2023; 14():1093194. PubMed ID: 37180706
[No Abstract] [Full Text] [Related]
17. Kidney Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Systematic Review and Bayesian Network Meta-Analysis.
Trisal SR; Low G; Pathan F; Gangadharan Komala M
Clin J Am Soc Nephrol; 2023 Mar; 18(7):843-9. PubMed ID: 36999976
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis.
Yamani N; Ahmed A; Ruiz G; Zubair A; Arif F; Mookadam F
Cardiooncology; 2024 Jun; 10(1):37. PubMed ID: 38886852
[TBL] [Abstract][Full Text] [Related]
19. Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Matsumoto H; Somekawa K; Horita N; Ueda S; Kaneko M; Kaneko A; Fukuda N; Izawa A; Kamimaki C; Tanaka K; Murohashi K; Fuji H; Tagami Y; Aoki A; Watanabe K; Hara Y; Kobayashi N; Kaneko T
Ther Adv Med Oncol; 2023; 15():17588359231198453. PubMed ID: 37720498
[TBL] [Abstract][Full Text] [Related]
20. Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma: Protocol for a rapid systematic review.
Kelly SE; Wang X; Hsieh SC; Abdul-Wahid A; Derry M; Skidmore B; Wells GA
MethodsX; 2024 Jun; 12():102730. PubMed ID: 38779442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
